Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma.

Cesar Rodriguez, Donna Catamero
{"title":"Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma.","authors":"Cesar Rodriguez,&nbsp;Donna Catamero","doi":"10.6004/jadpro.2023.14.3.14","DOIUrl":null,"url":null,"abstract":"<p><p>Therapeutic options for patients with multiple myeloma have multiplied in the past decade. However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma is characterized by genetic and cytogenetic alterations that drive resistance and result in progressively shorter durations of remission to each subsequent therapy. At JADPRO Live 2022, presenters discussed the multifactorial process for choosing the right therapy for a particular patient and strategies to manage unique treatment complications associated with novel treatment modalities used for patients with relapsed/refractory multiple myeloma.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 3","pages":"252-256"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c2/ad/jadpro-14-252.PMC10184840.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Advanced Practitioner in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2023.14.3.14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Therapeutic options for patients with multiple myeloma have multiplied in the past decade. However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma is characterized by genetic and cytogenetic alterations that drive resistance and result in progressively shorter durations of remission to each subsequent therapy. At JADPRO Live 2022, presenters discussed the multifactorial process for choosing the right therapy for a particular patient and strategies to manage unique treatment complications associated with novel treatment modalities used for patients with relapsed/refractory multiple myeloma.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
复发/难治性多发性骨髓瘤患者的新疗法
在过去的十年中,多发性骨髓瘤患者的治疗选择成倍增加。然而,多发性骨髓瘤仍然是一种无法治愈的疾病,复发/难治性骨髓瘤的特点是遗传和细胞遗传改变,这些改变会导致耐药性,并导致每次后续治疗的缓解持续时间逐渐缩短。在JADPRO Live 2022上,演讲者讨论了为特定患者选择正确治疗的多因素过程,以及与复发/难治性多发性骨髓瘤患者使用的新治疗方式相关的独特治疗并发症的管理策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Diversity, Equity, and Inclusion in Multiple Myeloma: A Call to Action A Real-World Evidence Primer for Advanced Practice Providers: Integrating P-Reality X Into Shared Decision-Making for People With HR+/HER2− Metastatic Breast Cancer Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network’s MYLUNG Consortium Beyond Standard Endocrine Therapy: A New Adjuvant Treatment in High-Risk Early Breast Cancer Evaluating the User-Perceived Benefit of a Virtual Lung Cancer Patient Education and Support Community: LVNG With Lung Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1